View Past PerformanceLight AI バランスシートの健全性財務の健全性 基準チェック /66Light AIの総株主資本はCA$3.7M 、総負債はCA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれCA$5.0MとCA$1.2Mです。主要情報0%負債資本比率CA$0負債インタレスト・カバレッジ・レシオn/a現金CA$4.56mエクイティCA$3.71m負債合計CA$1.25m総資産CA$4.96m財務の健全性に関する最新情報お知らせ • Apr 17Light AI Inc. Auditor Raises 'Going Concern' DoubtLight AI Inc. filed its Annual on Apr 15, 2025 for the period ending Dec 31, 2024. In this report its auditor, SHIM & Associates LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.すべての更新を表示Recent updatesお知らせ • Jun 04Light AI Initiates FDA Pivotal Clinical Trial for QuickScan Strep a Software as a Medical DeviceLight AI Inc. has received ethics committee approval to commence the pivotal clinical trial intended to generate clinical evidence to support a future submission to the U.S. Food and Drug Administration for potential marketing authorization of QuickScan Strep A as a Class II medical device. The study protocol and design are informed by prior regulatory interactions, including pre-submission feedback received by the Company during its 2024 FDA Q-Sub process. QuickScan Strep A is being developed as a smartphone-enabled software platform intended to analyze throat images and provide an AI-supported assessment for suspected Strep A infection. The software remains investigational and has not been cleared or approved by the FDA or other regulatory authorities for commercial diagnostic use. The pivotal study is expected to enroll participants presenting with symptoms consistent with pharyngitis and is designed to compare the diagnostic performance of QuickScan Strep A against throat culture, an established clinical reference standard. Predefined study endpoints include diagnostic outcome measures, usability assessments, and patient management-related measures intended to support evaluation of software performance and a future FDA submission. Strep A pharyngitis is a common condition evaluated across primary care, urgent care, pediatric, pharmacy and community healthcare settings. Subject to successful clinical validation, regulatory authorization and commercial adoption, Light AI believes there may be future opportunities for software-enabled assessment technologies to support healthcare delivery and patient management pathways. The Company expects to provide updates regarding study progress, enrollment milestones, and timing considerations as appropriate and in accordance with applicable securities disclosure obligations.お知らせ • Jun 02Light AI Inc., Annual General Meeting, Jul 22, 2026Light AI Inc., Annual General Meeting, Jul 22, 2026. Location: british columbia, vancouver Canadaお知らせ • May 22Light AI Inc. announced that it expects to receive CAD 5 million in fundingLight AI Inc. announced a private placement with MV Capital LP to issue 5,000 secured convertible debenture units at an issue price of CAD 1,000 for the proceeds of CAD 5,000,000 on May 21, 2026. Each Unit will comprise of (i) a 12.0% secured convertible debenture of the Company in the principal amount equal to CAD 1,000 (each, a "Convertible Debenture") with interest compounded quarterly and payable on the earlier of the Maturity Date (as defined hereafter), prepayment or conversion and maturing 24 months from the closing of the Financing (the "Maturity Date"), and (ii) 8,000 common share purchase warrants (each, a "Warrant"), each Warrant being exercisable for a period of 36 months following the closing of the Financing (the "Closing Date") to purchase one common share of the Company (each, a "Warrant Share") at an exercise price of CAD 0.25 per Warrant Share. The Financing is expected to close on or around June 19, 2026, and is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Exchange.お知らせ • Jan 20+ 1 more updateLight Ai Inc. Announces Transition to A Fractional Chief Financial OfficerLight AI Inc. announced that George Reznik, Chief Financial Officer, is transitioning from the Company with the engagement of a part time fractional Chief Financial Officer.お知らせ • Dec 05Light AI Inc. Announces Transition Of Anthony Schaller From President And Chief Technology Officer To Advisory RoleLight AI Inc. announced that the Company's President and Chief Technology Officer, Mr. Anthony Schaller, has transitioned from the Company's President and Chief Technology Officer to an advisory role. Mr. Schaller has been instrumental in leading the Company's product development initiatives since late 2024 culminating with the Company's first version of its commercially oriented software completion. The Company is now transitioning to focus on its regulatory and commercialization initiatives.お知らせ • Nov 19Light AI Inc. Announces the Completion of Version 1.0 of its Commercial Software PlatformLight AI Inc. announced the completion of Version 1.0 of its commercial software platform. The software leverages proprietary AI algorithms to analyze smartphone images--initially focused on detecting Group A Streptococcus ("Strep A")--delivering rapid, accurate results without the need for swabs or lab tests. The app-based solution is designed for use on both iOS and Android devices, enabling broad accessibility and scalability. Light AI plans to initiate a pilot study with a major global healthcare provider to confirm the performance in managing pharyngitis cases in a real-world clinical urgent care medical setting. The pilot is expected to pave the way for initial anticipated commercial distribution and global expansion. Beyond pharyngitis, Light AI's platform is designed to expand into other diagnostic areas, including eye and skin conditions. The Company's broader vision is to create a cloud-based "Digital Clinical Lab" that transforms smartphones into accessible diagnostic tools, reducing reliance on traditional lab infrastructure.お知らせ • Oct 22Light AI Inc. Announces Board ChangesLight AI Inc. announced the appointment of two new directors to its board of directors, Mr. Robert Cartagena and Mr. Mario Vetro. Robert Cartagena is co-founder and managing partner of Mill Street Equity Partners LLC (formerly Mill Street Partners LLC), a specialty investment strategy development firm focused on middle-market dental and medical device companies. Robert had a 33-year career as a C-level executive and or board member for various dental manufacturing companies including Discus Dental LLC and DenMat Holdings LLC, serving as Chief Operating Officer for each firm. At both companies Robert led the development and launch of products which are now household brands in the dental industry in product categories such as surgical lasers, dental materials, professional teeth whitening, magnification and more. He has created tremendous value at various companies through new product development, sales and marketing, as well as buy-side and sell-side M&A in both private and public environments. Mario Vetro brings substantial expertise in structuring and raising capital for growth companies with a focus on technology and the natural resources sector. He currently serves as CEO of Commodity Partners Inc, a boutique merchant bank and advisory firm. There, he played a pivotal role in the co-founding of K92 Mining Inc., a company listed on the TSX, leading to the establishment of a world-class gold discovery and mining operation in Papua New Guinea. Building upon this success, Mr. Vetro excels at assembling formidable leadership teams, securing equity capital, and devising strong business strategies. The Company also announced the Mr. Hugh Cleland is transitioning from the Company's Board of Directors due to health reasons. Mr. Cleland has been instrumental in the Company's transition to a public company and supporting the Company in its financing and investor relations initiatives.お知らせ • Sep 05Light AI Inc. Announces Transition of Thomas Scarnecchia from Chief Operating Officer to an Advisory Role, Effective September 1, 2025Light AI Inc. announced the transition of its Chief Operating Officer ("COO"), Thomas Scarnecchia, to an advisory role primarily supporting the Company's regulatory initiatives effective September 1, 2025.お知らせ • Jul 08Light Ai Inc. Achieves Key Internal Milestones in the Development of Its Wellness Strep A Screening ApplicationLight AI Inc. announced that it has achieved key internal milestones in the development of its Wellness Strep A screening application. The Company's AI powered software platform is currently undergoing internal user testing by Light AI and its low and middle income countries go-to-market partner, Tech Care For All. The Company continues to progress with its initial commercialization efforts for its Wellness Application, inclusive of potential targeted market-demonstration deployments with pharmacy companies. Commercial availability of the Company's Wellness Application remains targeted for late 2025. The global AI healthcare market is projected to reach USD 110.6 billion by 2030 from USD 21.7 billion in 2025, at a CAGR of approximately 39% based upon adoption to new AI health and wellness solutions. The market is anticipated to grow due to the growing investments & funding by public-private organizations, the fast proliferation of AI in the healthcare industry, and the rising focus on developing human-aware AI systems. The market is experiencing growth due to increasing demand for enhanced services due to an unequal ratio between the healthcare workforce and patient numbers. However, inadequate IT infrastructure and inability to adopt AI-based healthcare solutions in emerging economies are estimated to pose a challenge to market growth to be addressed.お知らせ • May 02Light AI Inc. Moves Forward on Third 2025 Wellness Commercialization PlanLight AI Inc. announced that it continues to make solid progress towards its Wellness App Third Quarter 2025 commercialization consistent with the Company's prior announcement. Progress is being made on the Wellness App's innovative and intuitive UI design which will provide a seamless and empowering user experience. The Company anticipates showcasing a closed demo of its Wellness App within approximately 90 days to support its pre-commercialization initiatives. Built with experienced oversight and cutting-edge design principles at its core the AI oriented UI offers a seamless, beautifully easy to use navigation experience. Every touchpoint has been designed, reviewed, debated and engineered to make it easy for users to indicate their symptoms of concern, move to a scan, and quickly receive feedback with recommended next steps. Highlights of the Wellness App UI include: Streamlined Navigation - Clear map of the journey along with simplified menus create an experience easy for users to navigate; Cross-platform consistency - Whether users are on an IOS or Android device, the experience remains consistent and engaging; Personalized History and Resources - Users can see prior results and build a baseline of scan results, healthy or in response to reported symptoms; and Vibrant, Engaging Intuitive Visuals - The vibrant colour palette and typography promote a sense of calm, engagement and positivity. The innovative and intuitive UI design will roll out to users in a staggered release to allow time for feedback and improvement before full commercial launch anticipated in late 2025.お知らせ • Apr 17Light AI Inc. Auditor Raises 'Going Concern' DoubtLight AI Inc. filed its Annual on Apr 15, 2025 for the period ending Dec 31, 2024. In this report its auditor, SHIM & Associates LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Apr 16Light AI Inc. Announces Expansion of Its Wellness PlatformLight AI Inc. announced that its innovative wellness platform, anticipated to launch in Third Quarter of 2025, is expanding its capabilities to help users rule out COVID-19 and conjunctivitis (pink eye) in addition to Strep A. The wellness platform is a direct-to-consumer product designed to support the quick detection and management of these conditions and will serve as a cornerstone in Light AI's expanding suite of healthcare tools aimed at supporting millions of families and individuals worldwide. These additional medical conditions expand Light AI's addressable market and are anticipated to enhance revenue and opportunities for licensing and partnership. This illustrates the Company's progress toward its ultimate goal of being a one-stop application to enhance health and wellness. Group A Strep, a common yet potentially serious infection, can cause significant health complications if not managed properly. Light AI's app will leverage advanced machine learning (ML) algorithms to provide accurate and timely diagnosis, empowering families to manage this condition more effectively. Conjunctivitis is a highly infectious condition affecting approximately 6 million people annually in the USA alone, and can lead to severe complications such as cellulitis, orbital cellulitis, keratitis, corneal ulcers, and scarring, potentially increasing the risk of permanent vision impairment if left untreated. Light AI's dedicated team is currently working to advance diagnostics on healthcare issues and will provide updates as new algorithms are refined. This expanded ecosystem will not only provide economies of scale to support market demand but will also generate valuable data to enhance predictive algorithms for future healthcare solutions.お知らせ • Apr 01Light Ai Inc. Appoints Anthony Schaller as President and CTOLight AI Inc. announce the appointment of Anthony Schaller as the new President and CTO. Mr. Schaller is a globally recognized leader in the technology industry. Since October 2024, Mr. Schaller has been assessing and planning Light AI's app platform and cloud-based development activities, driving Light AI's technology road map and related commercialization initiatives. Four Decades Of Development Experience Mr. Schaller has four decades of extensive experience in global strategy, innovation, research and development, and product and technology development and commercialization across enterprise and consumer markets in North America including: Creating and implementing the platform for digital media distribution to portable music devices as well as in the home, inclusive of the MPEG-1 Audio Layer 3 (MP3) player and Advanced Audio Coding (AAC) industry file format to compress and store audio; Leading technology innovation and transformation efforts at CitySearch /Ticketmaster; Leader in chemical R&D solving the problem of database access in different formats and systems enabling global pharmaceutical researchers to accelerate drug discovery; Led pioneering development of distributed databases and file systems starting with the Andrew Project at Carnegie Mellon University (CMU) and Ingres; Led technology scale-up and commercialization of Match.com (pioneer internet-based dating site), responsible for approximately 40x increase in user traffic and a 10x increased market capitalization, resulting in a buyout; and Senior Operating advisor for a global private equity firm with over $60 billion in assets under management providing operational strategy, SaaS transformation of process and products, margin efficiency /improvement leadership as well as due diligence on strategic acquisitions.財務状況分析短期負債: OHCF.Fの 短期資産 ( CA$4.9M ) が 短期負債 ( CA$1.2M ) を超えています。長期負債: OHCF.Fには長期負債はありません。デット・ツー・エクイティの歴史と分析負債レベル: OHCF.Fは負債がありません。負債の削減: OHCF.F 5 年前には負債がありませんでした。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: OHCF.Fは、前回報告された フリーキャッシュフロー に基づいて7か月分の十分な キャッシュランウェイ を有していますが、その後追加の資本を調達しました。キャッシュランウェイの予測: OHCF.Fフリーキャッシュフロー 推定値 に基づいて5か月間十分なキャッシュランウェイがあると予測されていますが、その後、追加の資本を調達しました。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 23:15終値2026/06/11 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Light AI Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 17Light AI Inc. Auditor Raises 'Going Concern' DoubtLight AI Inc. filed its Annual on Apr 15, 2025 for the period ending Dec 31, 2024. In this report its auditor, SHIM & Associates LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Jun 04Light AI Initiates FDA Pivotal Clinical Trial for QuickScan Strep a Software as a Medical DeviceLight AI Inc. has received ethics committee approval to commence the pivotal clinical trial intended to generate clinical evidence to support a future submission to the U.S. Food and Drug Administration for potential marketing authorization of QuickScan Strep A as a Class II medical device. The study protocol and design are informed by prior regulatory interactions, including pre-submission feedback received by the Company during its 2024 FDA Q-Sub process. QuickScan Strep A is being developed as a smartphone-enabled software platform intended to analyze throat images and provide an AI-supported assessment for suspected Strep A infection. The software remains investigational and has not been cleared or approved by the FDA or other regulatory authorities for commercial diagnostic use. The pivotal study is expected to enroll participants presenting with symptoms consistent with pharyngitis and is designed to compare the diagnostic performance of QuickScan Strep A against throat culture, an established clinical reference standard. Predefined study endpoints include diagnostic outcome measures, usability assessments, and patient management-related measures intended to support evaluation of software performance and a future FDA submission. Strep A pharyngitis is a common condition evaluated across primary care, urgent care, pediatric, pharmacy and community healthcare settings. Subject to successful clinical validation, regulatory authorization and commercial adoption, Light AI believes there may be future opportunities for software-enabled assessment technologies to support healthcare delivery and patient management pathways. The Company expects to provide updates regarding study progress, enrollment milestones, and timing considerations as appropriate and in accordance with applicable securities disclosure obligations.
お知らせ • Jun 02Light AI Inc., Annual General Meeting, Jul 22, 2026Light AI Inc., Annual General Meeting, Jul 22, 2026. Location: british columbia, vancouver Canada
お知らせ • May 22Light AI Inc. announced that it expects to receive CAD 5 million in fundingLight AI Inc. announced a private placement with MV Capital LP to issue 5,000 secured convertible debenture units at an issue price of CAD 1,000 for the proceeds of CAD 5,000,000 on May 21, 2026. Each Unit will comprise of (i) a 12.0% secured convertible debenture of the Company in the principal amount equal to CAD 1,000 (each, a "Convertible Debenture") with interest compounded quarterly and payable on the earlier of the Maturity Date (as defined hereafter), prepayment or conversion and maturing 24 months from the closing of the Financing (the "Maturity Date"), and (ii) 8,000 common share purchase warrants (each, a "Warrant"), each Warrant being exercisable for a period of 36 months following the closing of the Financing (the "Closing Date") to purchase one common share of the Company (each, a "Warrant Share") at an exercise price of CAD 0.25 per Warrant Share. The Financing is expected to close on or around June 19, 2026, and is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Exchange.
お知らせ • Jan 20+ 1 more updateLight Ai Inc. Announces Transition to A Fractional Chief Financial OfficerLight AI Inc. announced that George Reznik, Chief Financial Officer, is transitioning from the Company with the engagement of a part time fractional Chief Financial Officer.
お知らせ • Dec 05Light AI Inc. Announces Transition Of Anthony Schaller From President And Chief Technology Officer To Advisory RoleLight AI Inc. announced that the Company's President and Chief Technology Officer, Mr. Anthony Schaller, has transitioned from the Company's President and Chief Technology Officer to an advisory role. Mr. Schaller has been instrumental in leading the Company's product development initiatives since late 2024 culminating with the Company's first version of its commercially oriented software completion. The Company is now transitioning to focus on its regulatory and commercialization initiatives.
お知らせ • Nov 19Light AI Inc. Announces the Completion of Version 1.0 of its Commercial Software PlatformLight AI Inc. announced the completion of Version 1.0 of its commercial software platform. The software leverages proprietary AI algorithms to analyze smartphone images--initially focused on detecting Group A Streptococcus ("Strep A")--delivering rapid, accurate results without the need for swabs or lab tests. The app-based solution is designed for use on both iOS and Android devices, enabling broad accessibility and scalability. Light AI plans to initiate a pilot study with a major global healthcare provider to confirm the performance in managing pharyngitis cases in a real-world clinical urgent care medical setting. The pilot is expected to pave the way for initial anticipated commercial distribution and global expansion. Beyond pharyngitis, Light AI's platform is designed to expand into other diagnostic areas, including eye and skin conditions. The Company's broader vision is to create a cloud-based "Digital Clinical Lab" that transforms smartphones into accessible diagnostic tools, reducing reliance on traditional lab infrastructure.
お知らせ • Oct 22Light AI Inc. Announces Board ChangesLight AI Inc. announced the appointment of two new directors to its board of directors, Mr. Robert Cartagena and Mr. Mario Vetro. Robert Cartagena is co-founder and managing partner of Mill Street Equity Partners LLC (formerly Mill Street Partners LLC), a specialty investment strategy development firm focused on middle-market dental and medical device companies. Robert had a 33-year career as a C-level executive and or board member for various dental manufacturing companies including Discus Dental LLC and DenMat Holdings LLC, serving as Chief Operating Officer for each firm. At both companies Robert led the development and launch of products which are now household brands in the dental industry in product categories such as surgical lasers, dental materials, professional teeth whitening, magnification and more. He has created tremendous value at various companies through new product development, sales and marketing, as well as buy-side and sell-side M&A in both private and public environments. Mario Vetro brings substantial expertise in structuring and raising capital for growth companies with a focus on technology and the natural resources sector. He currently serves as CEO of Commodity Partners Inc, a boutique merchant bank and advisory firm. There, he played a pivotal role in the co-founding of K92 Mining Inc., a company listed on the TSX, leading to the establishment of a world-class gold discovery and mining operation in Papua New Guinea. Building upon this success, Mr. Vetro excels at assembling formidable leadership teams, securing equity capital, and devising strong business strategies. The Company also announced the Mr. Hugh Cleland is transitioning from the Company's Board of Directors due to health reasons. Mr. Cleland has been instrumental in the Company's transition to a public company and supporting the Company in its financing and investor relations initiatives.
お知らせ • Sep 05Light AI Inc. Announces Transition of Thomas Scarnecchia from Chief Operating Officer to an Advisory Role, Effective September 1, 2025Light AI Inc. announced the transition of its Chief Operating Officer ("COO"), Thomas Scarnecchia, to an advisory role primarily supporting the Company's regulatory initiatives effective September 1, 2025.
お知らせ • Jul 08Light Ai Inc. Achieves Key Internal Milestones in the Development of Its Wellness Strep A Screening ApplicationLight AI Inc. announced that it has achieved key internal milestones in the development of its Wellness Strep A screening application. The Company's AI powered software platform is currently undergoing internal user testing by Light AI and its low and middle income countries go-to-market partner, Tech Care For All. The Company continues to progress with its initial commercialization efforts for its Wellness Application, inclusive of potential targeted market-demonstration deployments with pharmacy companies. Commercial availability of the Company's Wellness Application remains targeted for late 2025. The global AI healthcare market is projected to reach USD 110.6 billion by 2030 from USD 21.7 billion in 2025, at a CAGR of approximately 39% based upon adoption to new AI health and wellness solutions. The market is anticipated to grow due to the growing investments & funding by public-private organizations, the fast proliferation of AI in the healthcare industry, and the rising focus on developing human-aware AI systems. The market is experiencing growth due to increasing demand for enhanced services due to an unequal ratio between the healthcare workforce and patient numbers. However, inadequate IT infrastructure and inability to adopt AI-based healthcare solutions in emerging economies are estimated to pose a challenge to market growth to be addressed.
お知らせ • May 02Light AI Inc. Moves Forward on Third 2025 Wellness Commercialization PlanLight AI Inc. announced that it continues to make solid progress towards its Wellness App Third Quarter 2025 commercialization consistent with the Company's prior announcement. Progress is being made on the Wellness App's innovative and intuitive UI design which will provide a seamless and empowering user experience. The Company anticipates showcasing a closed demo of its Wellness App within approximately 90 days to support its pre-commercialization initiatives. Built with experienced oversight and cutting-edge design principles at its core the AI oriented UI offers a seamless, beautifully easy to use navigation experience. Every touchpoint has been designed, reviewed, debated and engineered to make it easy for users to indicate their symptoms of concern, move to a scan, and quickly receive feedback with recommended next steps. Highlights of the Wellness App UI include: Streamlined Navigation - Clear map of the journey along with simplified menus create an experience easy for users to navigate; Cross-platform consistency - Whether users are on an IOS or Android device, the experience remains consistent and engaging; Personalized History and Resources - Users can see prior results and build a baseline of scan results, healthy or in response to reported symptoms; and Vibrant, Engaging Intuitive Visuals - The vibrant colour palette and typography promote a sense of calm, engagement and positivity. The innovative and intuitive UI design will roll out to users in a staggered release to allow time for feedback and improvement before full commercial launch anticipated in late 2025.
お知らせ • Apr 17Light AI Inc. Auditor Raises 'Going Concern' DoubtLight AI Inc. filed its Annual on Apr 15, 2025 for the period ending Dec 31, 2024. In this report its auditor, SHIM & Associates LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Apr 16Light AI Inc. Announces Expansion of Its Wellness PlatformLight AI Inc. announced that its innovative wellness platform, anticipated to launch in Third Quarter of 2025, is expanding its capabilities to help users rule out COVID-19 and conjunctivitis (pink eye) in addition to Strep A. The wellness platform is a direct-to-consumer product designed to support the quick detection and management of these conditions and will serve as a cornerstone in Light AI's expanding suite of healthcare tools aimed at supporting millions of families and individuals worldwide. These additional medical conditions expand Light AI's addressable market and are anticipated to enhance revenue and opportunities for licensing and partnership. This illustrates the Company's progress toward its ultimate goal of being a one-stop application to enhance health and wellness. Group A Strep, a common yet potentially serious infection, can cause significant health complications if not managed properly. Light AI's app will leverage advanced machine learning (ML) algorithms to provide accurate and timely diagnosis, empowering families to manage this condition more effectively. Conjunctivitis is a highly infectious condition affecting approximately 6 million people annually in the USA alone, and can lead to severe complications such as cellulitis, orbital cellulitis, keratitis, corneal ulcers, and scarring, potentially increasing the risk of permanent vision impairment if left untreated. Light AI's dedicated team is currently working to advance diagnostics on healthcare issues and will provide updates as new algorithms are refined. This expanded ecosystem will not only provide economies of scale to support market demand but will also generate valuable data to enhance predictive algorithms for future healthcare solutions.
お知らせ • Apr 01Light Ai Inc. Appoints Anthony Schaller as President and CTOLight AI Inc. announce the appointment of Anthony Schaller as the new President and CTO. Mr. Schaller is a globally recognized leader in the technology industry. Since October 2024, Mr. Schaller has been assessing and planning Light AI's app platform and cloud-based development activities, driving Light AI's technology road map and related commercialization initiatives. Four Decades Of Development Experience Mr. Schaller has four decades of extensive experience in global strategy, innovation, research and development, and product and technology development and commercialization across enterprise and consumer markets in North America including: Creating and implementing the platform for digital media distribution to portable music devices as well as in the home, inclusive of the MPEG-1 Audio Layer 3 (MP3) player and Advanced Audio Coding (AAC) industry file format to compress and store audio; Leading technology innovation and transformation efforts at CitySearch /Ticketmaster; Leader in chemical R&D solving the problem of database access in different formats and systems enabling global pharmaceutical researchers to accelerate drug discovery; Led pioneering development of distributed databases and file systems starting with the Andrew Project at Carnegie Mellon University (CMU) and Ingres; Led technology scale-up and commercialization of Match.com (pioneer internet-based dating site), responsible for approximately 40x increase in user traffic and a 10x increased market capitalization, resulting in a buyout; and Senior Operating advisor for a global private equity firm with over $60 billion in assets under management providing operational strategy, SaaS transformation of process and products, margin efficiency /improvement leadership as well as due diligence on strategic acquisitions.